GlassScriptPhysician profile
David H Grossman
NPI 1518942846
$816.62
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $34.98 · 2021: $229 · 2022: $161 · 2023: $222 · 2024: $30.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $129.35 | 2019-2023 | |
| Aspira Women'S Health INC | $108.31 | 2021 | |
| Pfizer INC. | $77.92 | 2020-2024 | |
| Amgen INC. | $70.52 | 2019-2023 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $64.76 | 2019-2023 | |
| Astellas Pharma US INC | $55.72 | 2022-2024 | Veozah |
| Exact Sciences Corporation | $43.43 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $35.78 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $35.48 | 2022-2023 | |
| Allergan, INC. | $34.42 | 2019 | |
| Myovant Sciences INC. | $34.07 | 2021-2022 | |
| Coopersurgical, INC. | $28.94 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $25.85 | 2023 | Myfembree |
| Amag Pharmaceuticals, INC. | $20.72 | 2019 | |
| Exeltis, USA INC. | $19.39 | 2023 | Slynd |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $16.82 | 2019 | |
| Evofem Biosciences, INC. | $15.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grossman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.